By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 120.49 |
Change Today | $ 6.44 |
% Change | 5.65 % |
52 Week High | $236.72 |
52 Week Low | $110.04 |
Volume | 231 |
Shares Issued | 145.80m |
Market Cap | $17,567m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 9 |
Neutral | 20 |
Sell | 0 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 453,075 @ $120.49 |
15:59 | 100 @ $120.41 |
15:59 | 100 @ $120.40 |
15:59 | 100 @ $120.40 |
15:59 | 200 @ $120.38 |
You are here: research